Safety and Efficacy of ActiGraft Pro Compared to Standard of Care in DFUs

NACompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

December 20, 2019

Primary Completion Date

March 31, 2024

Study Completion Date

April 1, 2024

Conditions
Diabetic FootChronic Ulcer
Interventions
DEVICE

ActiGraft

Whole Blood Clot (WBC) gel

DEVICE

Standard of Care

Alginate dressing, a non-adherent foam dressing, and an outer gauze wrap

Trial Locations (16)

19140

Temple University, Philadelphia

33073

Eric J Lullove DPM PA, Coconut Creek

33169

Barry University Clinical Research, North Miami Beach

33175

Future Health Research Clinic, Miami

36111

Institute for Advanced Wound Care, Montgomery

89148

Wahab Consulting and Research LLC, Las Vegas

90063

New Hope Podiatry Group Inc, Los Angeles

90073

Greater Los Angeles VA, Los Angeles

91342

Olive View UCLA Education & Research Institute, Sylmar

94117

Center for Clinical Research Inc, San Francisco

96720

Pacific Vascular Institute, Hilo

02118

Boston Medical Center, Boston

0000

Wound Care South Africa, Germiston

Unknown

Haute Care, Lyttelton

Acinadem Altunizade, Istanbul

0084

Eloquent Health & Wellness, Tyger Valley

All Listed Sponsors
lead

RedDress Ltd.

INDUSTRY

NCT04185558 - Safety and Efficacy of ActiGraft Pro Compared to Standard of Care in DFUs | Biotech Hunter | Biotech Hunter